Although preclinical studies have shown that the effective inhibition of NETs is an important measure in the treatment of RA, most relevant studies remain in preclinical studies, and approved drugs targeting NETs are very scarce, such as drugs targeting PAD4 that have not been approved for human use (94). This evidence concerns the gene PADI4 and rheumatoid arthritis.